Backer MV, Gaynutdinov TI, Gorshkova II, Crouch RJ, Hu T, Aloise R, Arab M, Przekop K, Backer JM
(2003)
J Controlled Release,
89,
499-511 |
Drug Studies |
None |
Protein recombinantly expressed as and refolded from inclusion bodies. |
Escherichia coli |
BL21(DE3) |
37.0 |
2 |
pET29a(+) |
Cells were grown in Circle Grow medium (Q-Biogen), expression was induced with 1mM IPTG when OD600 reached 0.5-0.7. Cells were grown for a further 2h at 37degC then harvested by centrifugation (15min x 5000g). |
IPTG |
OD 600 =
0.5-0.7 |
Sonication |
None |
None |
insoluble |
Dialysis |
BugBuster (Novagen)/CelLytic B (Sigma), HisBind buffer (Novagen) |
20mM TrisHCl, 100mM NaCl, 8M Urea pH 8.0 |
1:20mM TrisHCl 2M Urea, 1mM glutathione, 0.4mM oxidized glutathione, 0.5M arginine, pH 8.0/2: 20mM TrisHCl pH 8.0 |
None |
no tag |
8.0 |
25.0 |
|
|
GSH/GSSG |
1mM/0.4mM,1mM/0.4mM |
The cells were lysed using BugBuster reagent (Novagen) according to the instructions of the manufacturer. The inclusion bodies were were centrifuged and washed with BugBuster reagent, followed by CelLytic B reagent (Sigma) diluted 1:10 with water, and then finally 1x HisBind buffer (Novagen). The inclusion bodies were solubilized by sonication in solubilization buffer. The protein was then refolded by a 2-step dialysis process, firstly for 20h against 20 volumes of refolding buffer 1, then for 24h against 100 volumes of refolding buffer 2.
|
Enzyme activity |
None |
None,L-Arginine |
0.5M |
|
>95% |
Hu-VEGF - same protocol as for VEGF, see separate record no.1508
Other constructs also purified:
HuS (aa.18-125 or 18-127) - see separate protocols, records no.1507, 7k9h3
|